China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
GlobeAlert Desk · curated from South China Morning Post · East Asia
Chinese biotech deal making is moving beyond the licensing of individual drug candidates, as the country transforms from a follower to a global innovation leader, according to analysts. The latest transaction underscores that shift. Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion. InnoCare said it would use its...
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
What the desk knows about this story
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Single-source so far. Treat details as unconfirmed until more publishers report.
Not flagged as developing.
- China canada agree to lift more tariffsKidnappings · China · 1h ago
- Second jury cant agree on underworld murder chargeAttacks & Assaults · Japan · 1d ago
- Long March 12 | SatNet LEO Group TBD?Rocket Launches · CHN · now